CCL3 and neoplasm: In detail, there was no difference of systemic levels of CCL3 according to the tumor grade (WHO grade IV vs. grade II-III, median (IQR): 24.3 (17.8–35.1) vs. 20.7 (15.2–36.4) pg/mL, p = 0.232), while systemic levels of IL-8 (18.1 (18.1–25.2) vs. 13.6 (7.7–17.6) pg/mL, p = 0.012) and IL-10 (28.4 (14.5–40.6) vs. 16.6 (10.7–27.3) pg/mL, p = 0.018) were higher in patients with WHO grade IV tumors compared to WHO grade II-III tumors (Figure 2).